NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE153526 Query DataSets for GSE153526
Status Public on Dec 20, 2021
Title M249 melanoma cells: Vemurafenib and Selumetinib resistant through BRAF double minutes vs. parental
Organism Homo sapiens
Experiment type Genome variation profiling by array
Summary CGH profiling of M249 melanoma cell line treated with step-wise increasing Vemurafenib and Selumetinib to develop resistance (VSR). The resistance mechanims was through BRAF amplification in double minute (DM) format. The control cell line is untreated M249.
 
Overall design Two-condition experiment, M249 Parental vs M249 VSR DM. Biological replicates: 1 control replicate, 1 treated replicate.
 
Contributor(s) Song K, Graeber TG
Citation(s) 34930786
Submission date Jun 29, 2020
Last update date Mar 21, 2022
Contact name Kai Song
Organization name Gilead Sciences, Inc
Street address 333 Lakeside Dr
City Foster City
State/province CA
ZIP/Postal code 94404
Country USA
 
Platforms (1)
GPL10152 Agilent-021924 SurePrint G3 Human CGH Microarray 8x60K (Feature Number version)
Samples (2)
GSM4646499 M249 Parental
GSM4646500 M249 Vemurafenib and Selumetinib resistant through double minutes
Relations
BioProject PRJNA642898

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE153526_RAW.tar 13.3 Mb (http)(custom) TAR (of TXT)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap